What is the 13F Pro Quality Score for QTTB?

13F Pro ranks Q32 Bio Inc. (QTTB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View QTTB's current score at https://13fpro.ai/research/QTTB (free sign-up required for the full ranking).

Where does 13F Pro source QTTB data?

All Q32 Bio Inc. fundamentals and ownership data come directly from SEC EDGAR. Q32 Bio Inc. files with the SEC under CIK 1661998. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is QTTB in?

Q32 Bio Inc. (QTTB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is QTTB research updated on 13F Pro?

QTTB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Q32 Bio Inc.(QTTB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1661998 QTTB stock profile & AI dashboard →

13F Pro Quality Score

23.1/100

Rank #2,623 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

3.1/100

Profitability

30.0/100

Balance Sheet

2.5/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

94.2/100

Revenue Scale

30.0/100

Dilution Risk

17.1/100

QTTB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Q32 Bio Inc. (QTTB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores QTTB at 23.1/100 on a 32-signal composite quality model, placing it at rank #2,623 of 2,879 stocks — the bottom half of the AI-ranked universe. QTTB scores in the top quartile across institutional flow (94.2). Areas of concern include balance sheet strength (2.5) and revenue growth (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Q32 Bio Inc. reports net income of $-7.6M, free cash flow of $-6.3M. Top institutional holders of QTTB by reported 13-F value include ORBIMED ADVISORS, Atlas Venture Life Science Advisors,, Opaleye Management, based on the most recent SEC filings. QTTB trades on the Nasdaq exchange and files with the SEC under CIK 1661998. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QTTB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Q32 Bio Inc. directly from SEC EDGAR. Q32 Bio Inc.'s 13F Pro composite quality score has ranged between 10 and 23 since 2026, currently 23.1 — an improving long-term trajectory across 10 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-7.6M

Free Cash Flow

Q1 2026

$-6.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+100.0% YoY

$0.00FY 2024

FY21 $34.0MFY22 $3.2MFY23 $-6.7MFY24 $0.00

Net Income

+11.2% YoY

$-47.7MFY 2024

FY21 $-95.8MFY22 $-5.0MFY23 $-53.7MFY24 $-47.7M

Operating Income

-37.0% YoY

$-66.1MFY 2024

FY21 $-95.9MFY22 $-133.3MFY23 $-48.3MFY24 $-66.1M

EPS (Diluted)

+95.7% YoY

$-6.58FY 2024

FY21 $-1.73FY22 $-0.09FY23 $-153.96FY24 $-6.58

Total Assets

+96.2% YoY

$92.3MFY 2024

FY21 $211.7MFY22 $228.5MFY23 $47.1MFY24 $92.3M

Op. Cash Flow

-262.6% YoY

$-67.7MFY 2024

FY21 $-109.8MFY22 $-113.7MFY23 $-18.7MFY24 $-67.7M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$0.00 +100.0%	$-6.7M -307.3%	$3.2M -90.6%	$34.0M +1157.3%	$2.7M +62.2%	$1.7M
Net Income	$-47.7M +11.2%	$-53.7M -972.9%	$-5.0M +94.8%	$-95.8M +25.6%	$-128.7M -23.8%	$-103.9M
Operating Income	$-66.1M -37.0%	$-48.3M +63.8%	$-133.3M -38.9%	$-95.9M +26.3%	$-130.3M -18.5%	$-109.9M
EPS (Diluted)	$-6.58 +95.7%	$-153.96 -170966.7%	$-0.09 +94.8%	$-1.73	—	—
Total Assets	$92.3M +96.2%	$47.1M -79.4%	$228.5M +7.9%	$211.7M -19.7%	$263.7M -15.1%	$310.6M
Operating Cash Flow	$-67.7M -262.6%	$-18.7M +83.6%	$-113.7M -3.6%	$-109.8M -16.3%	$-94.3M -3.3%	$-91.4M

AI Insight: QTTB Ratio Trends

Q32 Bio transformed from deeply negative ROA of -47.8% in Q1 2026 to positive 52.2% on TTM basis, signaling dramatic operational turnaround.

• ROA improved from -67.3% in Q3 2024 to -47.8% in Q1 2026, then surged to positive 52.2% TTM.

• ROIC jumped from -66.7% in Q1 2026 to positive 46.2% on TTM basis, indicating strong capital efficiency gains.

• ROE reached 71.8% TTM after being negative -65.7% in Q1 2026, reflecting substantial profitability improvement.

⚠ Large gap between Q1 2026 quarterly metrics and TTM figures suggests potential volatility or one-off items affecting sustainability.

⚠ Missing operating margin and debt metrics limit visibility into underlying operational drivers and financial leverage.

Get alerted when QTTB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Q32 Bio Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of QTTB

ORBIMED ADVISORS LLC
$14.5M2,252,987 sh
Atlas Venture Life Science Advisors, LLC
$13.4M2,092,106 sh
Opaleye Management Inc.
$8.1M1,256,228 sh
Carlyle Group Inc.
$7.1M1,102,741 sh
ARCH Venture Management, LLC
$2.1M320,482 sh
ACORN CAPITAL ADVISORS, LLC
$2.0M315,052 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.0M306,401 sh
MACKENZIE FINANCIAL CORP
$1.6M246,304 sh
Sanofi
$1.6M244,083 sh
RENAISSANCE TECHNOLOGIES LLC
$1.3M206,915 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$14.5M	2,252,987
Atlas Venture Life Science Advisors, LLC	$13.4M	2,092,106
Opaleye Management Inc.	$8.1M	1,256,228
Carlyle Group Inc.	$7.1M	1,102,741
ARCH Venture Management, LLC	$2.1M	320,482
ACORN CAPITAL ADVISORS, LLC	$2.0M	315,052
VANGUARD CAPITAL MANAGEMENT LLC	$2.0M	306,401
MACKENZIE FINANCIAL CORP	$1.6M	246,304
Sanofi	$1.6M	244,083
RENAISSANCE TECHNOLOGIES LLC	$1.3M	206,915

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put QTTB on your watchlist

Track score changes the day Q32 Bio Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is QTTB a good stock to buy?

13F Pro's AI-powered analysis of Q32 Bio Inc. (QTTB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QTTB are available on the QTTB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own QTTB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QTTB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Q32 Bio Inc.'s investment landscape.